Long-term outcomes of low-dose dasatinib in older patients with chronic myeloid leukemia in chronic phase: an extended follow-up of the DAVLEC phase 2 trial - Report - MDSpire

Long-term outcomes of low-dose dasatinib in older patients with chronic myeloid leukemia in chronic phase: an extended follow-up of the DAVLEC phase 2 trial

  • By

  • Hiroshi Ureshino

  • Kazunori Murai

  • Takashi Kumagai

  • Tatsuji Mino

  • Kaichi Nishiwaki

  • Satoshi Wakita

  • Tomoharu Takeoka

  • Masayuki Mita

  • Chikashi Yoshida

  • Nobuhiko Uoshima

  • Toshihiro Fukushima

  • Junya Kuroda

  • Takeshi Kondo

  • Masahiro Chiba

  • Takuya Miyazaki

  • Katsuhiro Io

  • Tomoaki Ueda

  • Takaaki Ono

  • Kensuke Usuki

  • Takahiro Yamauchi

  • Katsumichi Fujimaki

  • Takayuki Ikezoe

  • Atsushi Kawaguchi

  • Shinya Kimura

  • May 28, 2026

  • 0 min

Share

Clinical Report: Long-term effects of low-dose dasatinib in elderly CML patients

Overview

{'add': 'The median follow-up duration was 68.1 months.'}

Background

Chronic myeloid leukemia (CML) is a lifelong disease, particularly affecting older adults who often present with multiple comorbidities. The use of tyrosine kinase inhibitors (TKIs) like dasatinib has transformed treatment outcomes, but the elderly population remains vulnerable to treatment-related adverse events. Understanding the long-term efficacy and safety of low-dose dasatinib in this demographic is crucial for optimizing treatment strategies.

Data Highlights

{'add': 'MMR: Major Molecular Response; MR4.0: Molecular Response 4.0; MR4.5: Molecular Response 4.5.'}

Key Findings

{'clarify': 'Explain the implications of HR values for achieving MMR.'}

Clinical Implications

{'expand': 'Provide examples of individual patient factors to consider.'}

Conclusion

{'add': 'Emphasize the necessity of long-term follow-up in CML management.'}

Related Resources & Content

  1. Author(s)/Org, Source, Year -- Long-term effects of low-dose dasatinib
  2. 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia | Leukemia
  3. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study
  4. The ASCO Post — Updated Findings Further Define Role of Tyrosine Kinase Inhibitors in CML
  5. The ASCO Post — Combination Treatment That Skips Chemotherapy May Be Effective for Older Patients With Philadelphia Chromosome–Positive ALL
  6. The ASCO Post — Study Findings on Novel Therapies for Hematologic Malignancies
  7. The ASCO Post — FDA Issues Safety Announcement on Dasatinib
  8. Updated Findings Further Define Role of Tyrosine Kinase Inhibitors in CML
  9. Combination Treatment That Skips Chemotherapy May Be Effective for Older Patients With Philadelphia Chromosome–Positive ALL
  10. Study Findings on Novel Therapies for Hematologic Malignancies
  11. 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia | Leukemia
  12. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial | Journal of Clinical Oncology
  13. Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial - ScienceDirect

Original Source(s)

Long-term outcomes of low-dose dasatinib in older patients with chronic myeloid leukemia in chronic phase: an extended follow-up of the DAVLEC phase 2 trial

  • by Hiroshi Ureshino, Kazunori Murai, Takashi Kumagai, Tatsuji Mino, Kaichi Nishiwaki, Satoshi Wakita, Tomoharu Takeoka, Masayuki Mita, Chikashi Yoshida, Nobuhiko Uoshima, Toshihiro Fukushima, Junya Kuroda, Takeshi Kondo, Masahiro Chiba, Takuya Miyazaki, Katsuhiro Io, Tomoaki Ueda, Takaaki Ono, Kensuke Usuki, Takahiro Yamauchi, Katsumichi Fujimaki, Takayuki Ikezoe, Atsushi Kawaguchi, Shinya Kimura

  • May 28, 2026

Related Content

Validation of a cervical CDO1/CELF4 methylation test for endometrial cancer: a prospective paired-sample comparison with intrauterine specimen

Reduced-intensity versus intensive induction in high-risk acute promyelocytic leukemia: a systematic review and meta-analysis

From AI-based image analysis to surgical decision support in prostate cancer: interdisciplinary application of the international radiomics platform